FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Search Menu Search FDA Submit search Featured Report a Product Problem Contact FDA FDA Guidance Documents Recalls, Market Withdrawals and Safety Alerts Press Announcements Warning Letters Advisory Committees…

Source: FDA Press Releases